ABSTRACT A multidrug-resistant (carbapenems, aztreonam+ avibactam, and cefiderocol)
ST167 Escherichia coli clinical isolate recovered from a patient hospitalized in Switzerland …

Background Cefiderocol and ceftazidime-avibactam plus aztreonam (CZA-ATM) are
preferred treatment regimens for New Delhi metallo-β-lactamase (NDM)-producing …

Cefiderocol is a novel siderophore-conjugated cephalosporin that is very promising for the
treatment of infections caused by MDR bacteria. Its main advantages reside in its stability …

Cefiderocol resistance is increasingly reported in New Delhi metallo-β-lactamase–
producing Enterobacterales. Genomic and phenotypic analysis of Escherichia coli sequence …

Cefiderocol has been approved in the United States and Europe but not in China. We aim to
evaluate carbapenem-resistant Enterobacterales (CRE) susceptibility to cefiderocol to …

We examined the in vitro susceptibility of meropenem-nonsusceptible Enterobacterales,
Pseudomonas aeruginosa, and Acinetobacter baumannii complex isolates from five …

Background Cefiderocol is a novel siderophore cephalosporin active against MDR Gram-
negative bacilli, including MBL-harbouring Enterobacterales. The detection of multiple …

Background As cefiderocol is increasingly being prescribed in clinical practice, it is critical
that we understand key mechanisms contributing to acquired resistance to this agent …

Cefiderocol is a promising novel siderophore cephalosporin for the treatment of multidrug-
resistant Gram-negative bacilli and with stability against degradation by metallo-β …

Cefiderocol, a siderophore-containing cephalosporin with broad-spectrum antimicrobial
activity against many β-lactam-resistant Gram-negative bacteria, was tested by broth …